Healthcare Feb 07, 2023 12:11 PM (GMT+8) · EqualOcean
ForLong Biotech (Chinese: 复融生物), a biotech company focusing on the development of recombinant protein drug such as cytokines, announced that it had completed a CNY 100 million Series A funding round, which was led by Puhua Capital (Chinese: 普华资本) and followed by RenHe Capital (Chinese: 人合资本), FOF Capital (Chinese: 方富创投) , SND Venture Capital (Chinese: 苏高新创投), SND Sci-Tech innovation Angel (Chinese: 苏高新科创天使) , and HuangPu Fund (Chinese: 黄埔医药基金). Existing investor DongKai Venture Capital (Chinese: 东凯风投) continued to invest and HaoYue Capital (Chinese: 浩悦资本) acted as the exclusive financial adviser. Proceeds will be used to increase R&D investment, accelerate the registration and clinical research of pipelines, and expand business in recombinant proteins.